Intellectual Property Law
New Matter FALL 2023, VOLUME 48, EDITION 3
Content
- 2023 Dc Delegation Trip Report
- 2023 New Matter Author Submission Guidelines
- ANDY WARHOL FOUNDATION FOR THE VISUAL ARTS V. GOLDSMITH: Expanding the Degree of SimilarityâTrimming Transformative Use
- DARRABY GLIB NOTES⢠Andy Warhol Foundation Supreme Court Opinion: Highlights And Sound Bites
- INTELLECTUAL PROPERTY SECTION Executive Committee 2022-2023
- INTELLECTUAL PROPERTY SECTION Interest Group Representatives 2022-2023
- Intellectual Property Section New Matter Editorial Board
- IS ALL FAIR IN POP ART AND CELEBRITY PHOTOGRAPHY (PART II)? In Which the Justices Turn to Economics to Level the Playing Field for Human Creatives
- Letter From the Chair
- Letter From the Editor-in-chief
- Mickey Mouse and the Public Domain
- Mitigating Ai Bias With Responsible Ai Design
- Ninth Circuit Report
- Online Cle For Participatory Credit
- Patentability of Artificial Intelligence On the Precipice of Reform
- Quarterly International Ip Law Update
- Recent Disqualification Precedent Raises Interesting Questions About Computer Access and Data Rights
- Six Things To Know About the California Privacy Rights Act
- Table of Contents
- The California Lawyers Association Intellectual Property Alumni
- The Licensing Corner
- Trade Secret Report
- Ttab Decisions and Developments
- Federal Circuit Report
FEDERAL CIRCUIT REPORT
Naveed Hasan
Reichman Jorgensen Lehman & Feldberg LLP
[With contributions by Philip Eklem, Reichman Jorgensen Lehman & Feldberg LLP.]
This article discusses the Supreme Court’s decision in Amgen Inc. v. Sanofi1 as to the issues related to the enablement requirement of 35 U.S.C. § 112(a).2 In Amgen, the Court affirmed the Federal Circuit’s decision that Amgen’s patent claims did not satisfy the enablement requirement.3While the case primarily related to the enablement requirement of 35 U.S.C. § 112(a), it also relates to the public policy surrounding claim scope. This article addresses the Court’s analysis and its impact on claim scope.